Cimzia: new TNF-alpha inhibitor

Cimzia is a new addition to the management of moderate to severely active rheumatoid arthritis in combination with methotrexate or as monotherapy.

PHARMACOLOGY

Certolizumab pegol is a PEGylated formulation of a humanized monoclonal antibody specific for tnf-α.

CLINICAL STUDIES

In two studies comparing the use of certolizumab and MTX to placebo and MTX, significantly more patients in the certolizumab groups achieved the American College of Rheumatology 20 per cent criteria for improvement (ACR20) at 24 weeks.1,2

The most common adverse effects in the trials were headache, hypertension, UTI, URTI and back pain.1,2

View Cimzia drug record

REFERENCES

  1. Keystone E et al. Arthritis Rheumatism 2008; 58:3319-29.
  2. Smolen J et al. Ann Rheum Dis 2009; 68:797-804.

Further information: UCB

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors associated with increased risk of lower-limb amputation in new study

SGLT2 inhibitors may be linked to a doubling in the...

New MIMS table helps prescribers choose asthma inhalers

New MIMS table helps prescribers choose asthma inhalers

Prescribers can now turn to a handy MIMS comparison...

LABA/Corticosteroid Combination Inhalers for the Treatment of Asthma

LABA/Corticosteroid Combination Inhalers for the Treatment of Asthma

Key information on asthma combination inhalers.

MIMS Learning's top 25 learning modules in 2018: which topics were the hottest?

MIMS Learning's top 25 learning modules in 2018: which topics were the hottest?

Discover the hottest topics in primary care learning,...